Who is the CEO of Hard to Treat Diseases Inc.?

Shimin Yuan is a business executive who currently serves as the CEO of Hard to Treat Diseases Inc..

What is the Revenue Growth of Hard to Treat Diseases Inc.?

Revenue growth data for Hard to Treat Diseases Inc. is currently unavailable.

What is Hard to Treat Diseases Inc. operating Margin?

Operating margin data for Hard to Treat Diseases Inc. is currently unavailable.

In which market sector does Hard to Treat Diseases Inc. operate?

Hard to Treat Diseases Inc. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Hard to Treat Diseases Inc. revenue growth?

Revenue growth data for Hard to Treat Diseases Inc. is currently unavailable.

Hard to Treat Diseases Inc.

HTDS•PNK

HealthcareBiotechnology

$0.00

$0.00(0.00%)

Hard to Treat Diseases Inc. (HTDS) Stock Overview

Explore Hard to Treat Diseases Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for HTDSStats details for HTDS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for HTDSAnalyst Recommendations details for HTDS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China.

CEO

Shimin Yuan

Headquarters

Room EF, 12F, Shenzhen

Founded

1998